The pharmacodynamic effect of terlipressin versus high-dose octreotide in reducing hepatic venous pressure gradient: a randomized controlled trial

Vasoactive drugs can reduce portal venous pressure and control variceal bleeding. However, few studies have explored the hemodynamic effects of terlipressin and high-dose octreotide in such patients. Our purpose was to evaluate the hemodynamic changes and safety of using terlipressin and high-dose o...

Full description

Saved in:
Bibliographic Details
Published in:Annals of translational medicine 2021-05, Vol.9 (9), p.793-793
Main Authors: Li, Bing, Chen, Jie, Zhang, Chun-Qing, Wang, Guang-Chuan, Hu, Jin-Hua, Luo, Jian-Jun, Zhang, Wen, Wei, Yi-Chao, Zeng, Xiao-Qing, Chen, Shi-Yao
Format: Article
Language:English
Subjects:
Original
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Vasoactive drugs can reduce portal venous pressure and control variceal bleeding. However, few studies have explored the hemodynamic effects of terlipressin and high-dose octreotide in such patients. Our purpose was to evaluate the hemodynamic changes and safety of using terlipressin and high-dose octreotide in patients with decompensated liver cirrhosis. A multi-center randomized controlled trial was conducted. Cirrhotic patients with a history of variceal bleeding were included. Terlipressin or high-dose octreotide was administered during the procedure of measuring hepatic venous pressure gradient (HVPG). Hemodynamic parameters and symptoms were recorded. A total of 88 patients were included. HVPG was significantly reduced at 10, 20, and 30 min after drug administration in the terlipressin group (16.3±6.4 14.7±5.9, 14.0±6.1, and 13.8±6.1, respectively, P
ISSN:2305-5839
2305-5839
DOI:10.21037/atm-20-6774